Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Investigation

• Publication date

  2015-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1172/JCI77958PMID 26098215PMCID PMC4563675
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Longitudinal Biomarker for the Extent of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis

  2015cited by this paper
• Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

  2014cited by this paper
• Prevalence of Anti–RNA Polymerase III Antibodies in Systemic Sclerosis: New Data From a French Cohort and a Systematic Review and Meta‐Analysis

  2014cited by this paper
• Faculty Opinions recommendation of Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma.

  2014cited by this paper
• Identification of Cadherin 11 as a Mediator of Dermal Fibrosis and Possible Role in Systemic Sclerosis

  2014cited by this paper
• Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.

  2014cited by this paper
• Regulation of renal fibrosis by Smad3 Thr388 phosphorylation.

  2014cited by this paper
• Scleroderma. From Pathogenesis to Comprehensive Management

  2013cited by this paper
• Integrin Modulating Therapies Prevent Fibrosis and Autoimmunity in Genetic Mouse Models of Scleroderma

  2013cited by this paper
• Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

  2013cited by this paper
• Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies.

  2012cited by this paper
• THERAPEUTIC TARGETS OF ALPD AND CIRRHOSIS Novel anti-fibrotic modalities for liver fibrosis: Molecular targeting and regenerative medicine in fibrosis therapy

  2012cited by this paper
• Interstitial lung disease in connective tissue disorders.

  2012cited by this paper
• How does TGF-β mediate tubulointerstitial fibrosis?

  2012cited by this paper
• Proteomic Identification of ADAM12 as a Regulator for TGF-β1-Induced Differentiation of Human Mesenchymal Stem Cells to Smooth Muscle Cells

  2012cited by this paper
• Comprar Scleroderma, From Pathogenesis To Comprehensive Management | John Varga | 9781441957733 | Springer

  2012cited by this paper
• Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

  2012cited by this paper
• Lineage tracing and genetic ablation of ADAM12+ perivascular cells identify a major source of profibrotic cells during acute tissue injury

  2012cited by this paper
• Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment.

  2012cited by this paper
• A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis

  2011cited by this paper
• Mechanisms and consequences of TGF-ß overexpression by podocytes in progressive podocyte disease

  2011cited by this paper
• A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis.

  2010cited by this paper
• Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis.

  2010cited by this paper
• Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies.

  2010cited by this paper
• Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.

  2009cited by this paper
• NADPH Oxidase-4 Mediates Myofibroblast Activation and Fibrogenic Responses to Lung Injury

  2009cited by this paper
• Cellular and molecular mechanisms of fibrosis

  2008cited by this paper
• Clinical trials in systemic sclerosis: lessons learned and outcomes

  2007cited by this paper
• Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.

  2007cited by this paper
• Differential effects of BMP‐2 and TGF‐β1 on chondrogenic differentiation of adipose derived stem cells

  2007cited by this paper
• Laser Capture Microdissection-Microarray Analysis of Focal Segmental Glomerulosclerosis Glomeruli

  2007cited by this paper
• Systemic sclerosis: a prototypic multisystem fibrotic disorder.

  2007cited by this paper
• The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor

  2007cited by this paper
• SPARC, an upstream regulator of connective tissue growth factor in response to transforming growth factor beta stimulation.

  2006cited by this paper
• [Cellular and molecular mechanisms of fibrosis].

  2006cited by this paper
• Cyclophosphamide versus placebo in scleroderma lung disease.

  2006cited by this paper
• Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis.

  2006influential reference
• Development of an in vitro potency assay for therapeutic TGFbeta antagonists: the A549 cell bioassay.

  2006influential reference
• Development of an in vitro potency bioassay for therapeutic IL-13 antagonists: The A-549 cell bioassay

  2006cited by this paper
• Open source clustering software.

  2004cited by this paper
• Activation of the TGF- β/Smad signaling pathway in focal segmental glomerulosclerosis

  2003cited by this paper
• Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis.

  2003cited by this paper
• Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.

  2000cited by this paper
• Transforming growth factors beta stimulate both thrombospondin-1 and CISP/thrombospondin-2 synthesis by bovine adrenocortical cells.

  1995cited by this paper
• Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis.

  1995cited by this paper
• Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts

  1993cited by this paper
• Autoantibody Reactive with RNA Polymerase III in Systemic Sclerosis

  1993cited by this paper
• Transforming growth factor-beta. Major role in regulation of extracellular matrix.

  1990cited by this paper
• Transforming Growth Factor‐β

  1990cited by this paper
• Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

  1988cited by this paper
• Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability.

  1988cited by this paper
• Transforming growth factor‐beta is a strong and fast acting positive regulator of the level of type‐1 plasminogen activator inhibitor mRNA in WI‐38 human lung fibroblasts.

  1987cited by this paper
• Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.

  1987cited by this paper
• Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro.

  1986cited by this paper
• Type beta transforming growth factor: a bifunctional regulator of cellular growth.

  1985cited by this paper
• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

  1980cited by this paper
• Preliminary criteria for the classification of systemic sclerosis (scleroderma).

  1980cited by this paper

• Immune Imbalance Drives Keloid Pathogenesis: Emerging Targets for Precision Immunotherapy.

  2026cites this paper
• Attenuation of Transforming Growth Factor‐β Signaling Promotes Complete Recovery of Trabecular Bone Structure Following Immobilization With Traumatic Spinal Cord Injury

  2026cites this paper
• A Narrative Review of Salivary Gland Extracellular Matrix and Sjögren’s Syndrome: Research Status and Future Prospects

  2026cites this paper
• Macrophage subtypes and pathways in autoimmune interstitial lung diseases: potential therapeutic targets

  2025cites this paper
• Epigenetic changes cause aberrantly high expression of SOX11, leading to systemic sclerosis.

  2025cites this paper
• Antifibrotic therapeutic strategies in systemic sclerosis: Critical role of the Wnt/β-catenin and TGF-β signal transduction pathways as potential targets.

  2025cites this paper
• Critical Role for Transglutaminase 2 in Scleroderma Skin Fibrosis and in the Development of Dermal Sclerosis in a Mouse Model of Scleroderma

  2025cites this paper
• Inhibiting TGF-β signaling pathway for disease therapy: challenges and opportunities.

  2025cites this paper
• Shifting Shapes: The Endothelial-to-Mesenchymal Transition as a Driver for Cancer Progression

  2025cites this paper
• Targeting fibroblasts in pathological bone formation: mechanisms and treatments

  2025cites this paper
• Identification of potential drug targets for erectile dysfunction with single‐cell RNA sequencing: A Mendelian randomization study

  2025cites this paper
• Endothelial-to-Mesenchymal Transition in Health and Disease: Molecular Insights and Therapeutic Implications

  2025cites this paper
• Exploring radiation-induced fibrosis: biological mechanisms and new frontiers in research and therapeutics.

  2025cites this paper
• Allergic Contact Dermatitis: Immunopathology and Potential Therapeutic Strategies

  2025cites this paper
• Emerging therapies for the treatment of systemic sclerosis

  2025cites this paper
• Anti-TGF-β treatment shows increased bone mass and strength in a novel mouse model for osteogenesis imperfecta type I.

  2025cites this paper
• Langerin+ Dendritic Cells in Cutaneous Fibrosis: The TGF-β1 Signaling Axis

  2025cites this paper
• Altered AP-1, RUNX, and EGR chromatin dynamics drive human fibrotic lung disease.

  2025cites this paper
• Breaking the cycle: should we target inflammation, fibrosis, or both?

  2025cites this paper
• An international perspective on the future of systemic sclerosis research

  2025cites this paper
• The role of TGF-β1 in chronic multilobar segmental bronchial stenosis and advances in targeted drug research

  2025cites this paper
• Comprehensive Review of Osteogenesis Imperfecta: Current Treatments and Future Innovations

  2025cites this paper
• Dual inhibition of TGFβ2,3 is severely toxic, whereas selective inhibition of TGFβ1, 2, or 3 and dual inhibition of TGFβ1,2 is generally tolerated In mouse and cynomolgus monkey toxicology studies.

  2025cites this paper
• Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis.

  2025cites this paper
• Radiation-Induced Fibrosis (RIF) in Head and Neck Squamous Cell Carcinoma (HNSCC): A Review

  2025cites this paper
• Concentrated Micronized Fat Ameliorates Skin Fibrosis in Bleomycin‐Induced Murine Model and Enhances Fat Graft Survival

  2025cites this paper
• Systemic Autoimmune Rheumatic Diseases-associated Interstitial Lung Disease

  2025cites this paper
• Restoration of Fli1 expression as a potential therapeutic approach in Systemic Sclerosis: Effects on age-associated B cells.

  2025cites this paper
• RUNX1 is expressed in a subpopulation of dermal fibroblasts and is associated with disease severity of systemic sclerosis.

  2025cites this paper
• RUNX1 is Expressed in a Subpopulation of Dermal Fibroblasts and Higher RUNX1 Levels are Associated with the Severity of Systemic Sclerosis

  2024cites this paper
• Corneal fibrosis: From in vitro models to current and upcoming drug and gene medicines.

  2024cites this paper
• A Phase 1a Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7303509, an Anti-TGFβ3 Antibody, in Healthy Volunteers

  2024cites this paper
• Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis

  2024cites this paper
• Current and Developing Pharmacologic Agents for Improving Skeletal Health in Adults with Osteogenesis Imperfecta

  2024cites this paper
• The clinical manifestations and molecular pathogenesis of radiation fibrosis

  2024cites this paper
• Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?

  2024cites this paper
• A modest proposal: targeting αv integrin-mediated activation of latent TGFbeta as a novel therapeutic approach to treat scleroderma fibrosis

  2024cites this paper
• Talabostat, fibroblast activation protein inhibitor, attenuates inflammation and fibrosis in systemic sclerosis

  2024cites this paper
• Clinical, mechanistic, and therapeutic landscape of cutaneous fibrosis

  2024cites this paper
• Inhibition of CD44 suppresses the formation of fibrotic scar after spinal cord injury via the JAK2/STAT3 signaling pathway

  2024cites this paper
• TGF-β signaling in health, disease and therapeutics

  2024cites this paper
• Pathogenesis of systemic sclerosis: an integrative review of recent advances

  2024cites this paper
• Fibrosis mechanisms in systemic sclerosis and new potential therapies.

  2024cites this paper
• Exploring the Antifibrotic Mechanisms of Ghrelin: Modulating TGF-β Signalling in Organ Fibrosis

  2024cites this paper
• The correlation between cancer stem cells and epithelial-mesenchymal transition: molecular mechanisms and significance in cancer theragnosis

  2024cites this paper
• Comprehensive Insights into Keloid Pathogenesis and Advanced Therapeutic Strategies

  2024cites this paper
• Epigenetic memory of radiotherapy in dermal fibroblasts impairs wound repair capacity in cancer survivors

  2024cites this paper
• Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy

  2024cites this paper
• THE CURRRENT LANDSCAPE OF ANTIFIBROTIC THERAPY ACROSS DIFFERENT ORGANS: A SYSTEMATIC APPROACH.

  2024cites this paper
• Altered AP-1, RUNX and EGR chromatin dynamics drive fibrotic lung disease

  2024cites this paper
• CD109 Attenuates Bleomycin-induced Pulmonary Fibrosis by Inhibiting TGF-β Signaling.

  2024cites this paper
• Isoform-selective TGF-β3 inhibition for systemic sclerosis.

  2024cites this paper
• TGF-β signaling: critical nexus of fibrogenesis and cancer

  2024cites this paper
• The Exciting Future for Scleroderma: What Therapeutic Pathways Are on the Horizon?

  2023cites this paper
• Advances in biological and targeted therapies for systemic sclerosis

  2023cites this paper
• Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis

  2023cites this paper
• Human Regulatory T Cells: Understanding the Role of Tregs in Select Autoimmune Skin Diseases and Post-Transplant Nonmelanoma Skin Cancers

  2023cites this paper
• Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy

  2023cites this paper
• A 24‐Week, Phase IIa, Randomized, Double‐Blind, Placebo‐Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis

  2023cites this paper
• Investigational drugs for the treatment of scleroderma: what’s new?

  2023cites this paper
• Treatable Traits in Systemic Sclerosis

  2023cites this paper
• Microvascular significance of TGF-β axis activation in COVID-19

  2023cites this paper
• MiR-141-3p-Functionalized Exosomes Loaded in Dissolvable Microneedle Arrays for Hypertrophic Scar Treatment.

  2023cites this paper
• Identification of Fibroinflammatory and Fibrotic Transcriptomic Subsets of Human Cutaneous Sclerotic Chronic Graft-Versus-Host Disease

  2023cites this paper
• Recent Advances in Treatment of Systemic Sclerosis and Morphea

  2023cites this paper
• The Communication from Immune Cells to the Fibroblasts in Keloids: Implications for Immunotherapy

  2023influential citation
• Fibroblast subpopulations in Systemic Sclerosis - Functional implications of individual subpopulations and correlations with clinical features.

  2023cites this paper
• In-silico prediction of TGF-β1 non-synonymous variants and their impact on binding affinity to Fresolimumab

  2023cites this paper
• [Update on targeted biopharmaceuticals in systemic sclerosis!]

  2023cites this paper
• Utilizing PK and PD Biomarkers to Guide the First-in-Human Starting Dose Selection of MTBT1466A: A Novel Humanized Monoclonal Anti-TGFβ3 Antibody for the Treatment of Fibrotic Diseases.

  2023cites this paper
• Positive Feedback Loops between Fibroblasts and the Mechanical Environment Contribute to Dermal Fibrosis.

  2023cites this paper
• Release of High-Mobility Group Box-1 after a Raynaud’s Attack Leads to Fibroblast Activation and Interferon-γ Induced Protein-10 Production: Role in Systemic Sclerosis Pathogenesis

  2023cites this paper
• Human dental pulp stem cells (hDPSCs) promote the lipofibroblast transition in the early stage of a fibro-inflammatory process

  2023cites this paper
• Skin Gene Expression Profiles in Systemic Sclerosis: From Clinical Stratification to Precision Medicine

  2023cites this paper
• Scleroderma Skin: How Is Treatment Best Guided by Data and Implemented in Clinical Practice?

  2023cites this paper
• Transfer learning in a biomaterial fibrosis model identifies in vivo senescence heterogeneity and contributions to vascularization and matrix production across species and diverse pathologies

  2023cites this paper
• Understanding and Therapeutically Targeting the Scleroderma Myofibroblast

  2022cites this paper
• Management of Connective Tissue Disease–related Interstitial Lung Disease

  2022cites this paper
• Targeting the nasty nestin to shoot lung fibrosis

  2022cites this paper
• Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges

  2022cites this paper
• Transforming growth factor–β1 in regulatory T cell biology

  2022cites this paper
• Transfer learning of an in vivo-derived senescence signature identifies conserved and tissue-specific senescence across species and diverse pathologies

  2022cites this paper
• The uPA System Differentially Alters Fibroblast Fate and Profibrotic Ability in Skin Fibrosis

  2022cites this paper
• Problems to Consider Before Determining the Regimen of the Treatment for Juvenile Systemic Sclerosis Treatment: A Case Report Where Tocilizumab Monotherapy Succeeded Efficiently and Safely

  2022cites this paper
• Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy

  2022cites this paper
• Targeting transforming growth factor- β (TGF-β) for treatment of osteogenesis imperfecta.

  2022cites this paper
• Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis

  2022cites this paper
• Systemic sclerosis in adults. Part II: Management and therapeutics.

  2022cites this paper
• Noninvasive Systemic Modalities for Prevention of Head and Neck Radiation-Associated Soft Tissue Injury: A Narrative Review.

  2022cites this paper
• Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis

  2022cites this paper
• CXCL4 drives fibrosis by promoting several key cellular and molecular processes.

  2022cites this paper
• Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics

  2022cites this paper
• Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis

  2022cites this paper
• Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants

  2022cites this paper
• Targeting cytokines and potentiality of JAK–STAT inhibition in systemic sclerosis

  2022cites this paper
• Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets

  2022cites this paper
• TGF-beta signal transduction: biology, function and therapy for diseases

  2022cites this paper
• Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity

  2022cites this paper
• Future Treatment Options in Systemic Sclerosis—Potential Targets and Ongoing Clinical Trials

  2022cites this paper
• Cartilage Oligomeric Matrix Protein, Diseases, and Therapeutic Opportunities

  2022cites this paper